UNITED THERAPEUTICS Corp — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
United Therapeutics reported Q2 2026 revenues of $783.3M (down 2% from $798.6M in Q2 2025), with net income of $333.0M (up 8% from $309.5M). The company submitted NDAs for ralinepag tablets in PAH and Nebulized Tyvaso in IPF, with expected approvals by end-2027. Major revenue drivers: Tyvaso DPI grew 4% to $326.6M; Nebulized Tyvaso declined 18% to $126.0M; Remodulin fell 6% to $126.3M. The company repurchased 2.76M shares ($1.5B) via ASR agreements and maintains $3.8B in cash/investments.
Why this rating
Two transformative pipeline catalysts (ralinepag, Nebulized Tyvaso in IPF) represent multi-billion-dollar upside potential relative to ~$11.2B market cap. Near-term revenue decline offset by strong cash position and robust pipeline advancement.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.